Compare Cadila Healthcare with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs NEULAND LABS - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE NEULAND LABS CADILA HEALTHCARE/
NEULAND LABS
 
P/E (TTM) x 36.4 53.9 67.6% View Chart
P/BV x 6.4 4.1 156.6% View Chart
Dividend Yield % 0.5 0.1 610.2%  

Financials

 CADILA HEALTHCARE   NEULAND LABS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
NEULAND LABS
Mar-20
CADILA HEALTHCARE/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs352754 46.7%   
Low Rs207247 83.5%   
Sales per share (Unadj.) Rs139.2594.5 23.4%  
Earnings per share (Unadj.) Rs11.812.6 93.1%  
Cash flow per share (Unadj.) Rs18.637.0 50.2%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %1.30.4 313.5%  
Book value per share (Unadj.) Rs101.4553.4 18.3%  
Shares outstanding (eoy) m1,023.7412.83 7,979.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.00.8 238.4%   
Avg P/E ratio x23.739.6 59.9%  
P/CF ratio (eoy) x15.013.5 111.3%  
Price / Book Value ratio x2.80.9 304.8%  
Dividend payout %29.815.8 187.9%   
Avg Mkt Cap Rs m286,0336,421 4,454.8%   
No. of employees `00013.41.3 1,045.6%   
Total wages/salary Rs m24,1451,236 1,954.2%   
Avg. sales/employee Rs Th10,632.75,949.4 178.7%   
Avg. wages/employee Rs Th1,801.2963.8 186.9%   
Avg. net profit/employee Rs Th898.5126.4 710.7%   
INCOME DATA
Net Sales Rs m142,5317,627 1,868.7%  
Other income Rs m1,13939 2,931.8%   
Total revenues Rs m143,6707,666 1,874.1%   
Gross profit Rs m24,1981,019 2,375.0%  
Depreciation Rs m6,965313 2,226.7%   
Interest Rs m3,418216 1,584.4%   
Profit before tax Rs m14,954529 2,825.8%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,198367 871.1%   
Profit after tax Rs m12,044162 7,430.9%  
Gross profit margin %17.013.4 127.1%  
Effective tax rate %21.469.4 30.8%   
Net profit margin %8.52.1 397.6%  
BALANCE SHEET DATA
Current assets Rs m87,1545,152 1,691.7%   
Current liabilities Rs m82,6943,576 2,312.3%   
Net working cap to sales %3.120.7 15.1%  
Current ratio x1.11.4 73.2%  
Inventory Days Days71105 68.0%  
Debtors Days Days9491 103.2%  
Net fixed assets Rs m133,2363,969 3,357.3%   
Share capital Rs m1,024129 793.8%   
"Free" reserves Rs m102,7336,971 1,473.8%   
Net worth Rs m103,7577,100 1,461.4%   
Long term debt Rs m32,146774 4,154.8%   
Total assets Rs m236,86612,310 1,924.2%  
Interest coverage x5.43.5 155.7%   
Debt to equity ratio x0.30.1 284.3%  
Sales to assets ratio x0.60.6 97.1%   
Return on assets %6.53.1 212.7%  
Return on equity %11.62.3 508.5%  
Return on capital %13.79.5 145.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,7525,187 1,017.1%   
Fx outflow Rs m14,5041,593 910.6%   
Net fx Rs m38,2483,594 1,064.2%   
CASH FLOW
From Operations Rs m25,054573 4,369.4%  
From Investments Rs m-10,123-487 2,079.5%  
From Financial Activity Rs m-10,942-55 19,967.2%  
Net Cashflow Rs m3,98933 12,236.2%  

Share Holding

Indian Promoters % 74.8 36.3 206.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 63.7 13.0%  
FIIs % 5.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 63.7 17.3%  
Shareholders   44,069 12,705 346.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   J.B.CHEMICALS  ALEMBIC  WYETH  ELDER PHARMA  SUVEN LIFE SCIENCES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

CADILA HEALTHCARE at All Time High; BSE HEALTHCARE Index Down 0.1% (Market Updates)

May 12, 2021 | Updated on May 12, 2021

CADILA HEALTHCARE share price has hit an all time high at Rs 640 (up 1.1%). The BSE HEALTHCARE Index is down by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are CADILA HEALTHCARE (up 1.1%) and ABBOTT INDIA . The top losers include TORRENT PHARMA (down 0.1%) and SANOFI INDIA (down 0.1%).

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 12, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - AUROBINDO PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS